RJA
PVLA

Raymond James & Associates’s Palvella Therapeutics PVLA Stock Holding History

Raymond James & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-375
Closed -$5.5K – 4099
2024
Q1 		$5.5K Hold
375
– – ﹤0.01% 3911
2023
Q4 		$5.46K Hold
375
– – ﹤0.01% 3814
2023
Q3 		$8.94K Hold
375
– – ﹤0.01% 3765
2023
Q2 		$4.96K Hold
375
– – ﹤0.01% 3823
2023
Q1 		$29.3K Hold
375
– – ﹤0.01% 3775
2022
Q4 		$31.2K Buy
375
+125
+50% +$10K ﹤0.01% 3756
2022
Q3 		$23K Hold
250
– – ﹤0.01% 3789
2022
Q2 		$37K Hold
250
– – ﹤0.01% 3825
2022
Q1 		$61K Sell
250
-13
-5% -$3.42K ﹤0.01% 3896
2021
Q4 		$79K Buy
263
+13
+5% +$4.16K ﹤0.01% 3900
2021
Q3 		$103K Sell
250
-25
-9% -$8.71K ﹤0.01% 3830
2021
Q2 		$84K Hold
275
– – ﹤0.01% 3864
2021
Q1 		$57K Hold
275
– – ﹤0.01% 3841
2020
Q4 		$55K Hold
275
– – ﹤0.01% 3618
2020
Q3 		$46K Sell
275
-38
-12% -$8.65K ﹤0.01% 3455
2020
Q2 		$78K Sell
313
-573
-65% -$134K ﹤0.01% 3329
2020
Q1 		$162K Buy
886
+32
+4% +$8.06K ﹤0.01% 3108
2019
Q4 		$247K Hold
854
– – ﹤0.01% 3204
2019
Q3 		$233K Buy
854
+63
+8% +$24.4K ﹤0.01% 3165
2019
Q2 		$298K Sell
791
-63
-7% -$18.8K ﹤0.01% 3019
2019
Q1 		$229K Buy
854
+13
+2% +$3.09K ﹤0.01% 3154
2018
Q4 		$179K Buy
841
+25
+3% +$7.75K ﹤0.01% 3175
2018
Q3 		$366K Buy
816
+416
+104% +$181K ﹤0.01% 2910
2018
Q2 		$162K Sell
400
-14
-3% -$6.66K ﹤0.01% 3325
2018
Q1 		$226K Buy
414
+186
+82% +$115K ﹤0.01% 3069
2017
Q4 		$137K Sell
228
-25
-10% -$11.6K ﹤0.01% 3156
2017
Q3 		$116K Buy
253
+65
+35% +$27.8K ﹤0.01% 3164
2017
Q2 		$76K Hold
188
– – ﹤0.01% 3145
2017
Q1 		$39K Buy
+188
New +$33.3K ﹤0.01% 3162
2016
Q4 		– Sell
-375
Closed -$55K – 3369
2016
Q3 		$55K Buy
+375
New +$49.8K ﹤0.01% 3075

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Raymond James & Associates's PVLA Position: Q2 2024 in Review

Raymond James & Associates sold out of Palvella Therapeutics (PVLA) in Q2 2024, closing a stake of 375 shares — an estimated $5.5K sold.

Raymond James & Associates first reported a position in PVLA in Q3 2016 and held it in 30 quarters. The position peaked at $366K in Q3 2018. 21 funds tracked by Wall St. Rank hold PVLA as of Q2 2024.

  • Raymond James & Associates reported no remaining Palvella Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 375 Palvella Therapeutics shares in Q2 2024, an estimated $5.5K.
  • Raymond James & Associates first reported a position in Palvella Therapeutics in Q3 2016 and held it in 30 quarters.
  • Raymond James & Associates's Palvella Therapeutics position peaked at $366K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.